Posts filed under: private data

SCOPE 2018 ta-Scan

Press Releases Published on February 12, 2018

MDCPartners announces 2018 innovation strategy this week at SCOPE Summit in Orlando (FL)

At the 9th annual SCOPE Summit, taking place in Orlando (Florida) this week, MDCPartners will present their two latest innovative designs to the public: ta-Scan Podium and InterSect. ta-Scan Podium is an online tablet application for Clinical Ops, Medical Affairs teams, and Medical Science Liaisons that enables users to find full profiles of all relevant Key Opinion Leaders and Key External Experts. InterSect is a desktop application that interfaces with the entire ta-Scan database on a semantic level. This unique query tool allows users to overlap internal data with the ta-Scan database and match and correlate the data in the system.

Both new innovative technologies are based on the organization’s well-known clinical business intelligence solution ta-Scan and its Semantic Search System. The patented Trial Cloud® and web mining software of ta-Scan, which is the largest semantically linked clinical database available on the web, combined with its powerful search capabilities, allow users to quickly find and analyze clinical data from multiple global public sources. The effortless delivery of in-depth and clear insights into any data point in the database is what classifies these tools as digital innovations.

This year’s SCOPE summit will focus on stimulating innovation, change, and personalized solutions to improve the clinical trial process. With hot topics such as clinical technology and innovation and artificial intelligence in clinical research, it’s important for exhibitors to stay on top of these latest developments. Where MDCPartners’ focus in the previous years was more on the introduction of new features and developments, this year it has shifted to more personalized solutions, with new modules being completely customizable to integrate private data.

“As a company which provides clinical intelligence, we believe it is crucial to gain greater insights into therapeutic area landscapes by using innovative and personalized solutions. That’s why we collaborate with our clients to answer the business questions they need. The goal of creating these new modules is not only to increase work efficiency, but also to make decision making more transparent and interoperable,” says CEO Mireille De Cré. MDCPartners will introduce the full product portfolio at the SCOPE summit and provide top pharma executives with private sessions to test and use the products live.

View GlobeNewswire press release: http://inpublic.globenewswire.com/releaseDetails.faces?rId=2168008

MDCPartners and ta-Scan at Big Data in Precision Medicine 2016 Washington, D.C.

Events Published on October 10, 2016

MDCPartners Innovation Partner Big Data in Precision Medicine Washington

Big Data in Precision Medicine

With ESMO 2016 coming to a close in Copenhagen, MDCPartners is getting ready for their next stop: we are this year’s Innovation Partner of the Big Data in Precision Medicine meeting, which will take place in the Capital Hilton in Washington, D.C. on November 1-2, 2016.

This meeting attracts 250-300 senior executives from across the drug development sector including Big Pharma, biotech, leading solution providers, government, healthcare and academia. The meeting addresses the opportunities and challenges of big and real-world data, and how machine learning and cognitive computing can be applied in the context of drug development. View the meeting’s streams and the meeting agenda here.

Private Clinical Trial Data in the Real-World Data Context

On Tuesday November 1 at 9:30 AM, MDCPartners’ Chief Scientific Officer David Cocker will present our findings on “The value case of private pharma clinical trial data in the real-world data context”.

Real-world data (RWD) is generally the term used to refer to any data which is collected outside of randomized clinical trials (RCT). The data can be from sources including patient data from hospitals and clinicians. The premise is that RWD combined with information from RCTs can provide better research outcomes and improved healthcare.

Unfortunately, available clinical trial information data is really not that big. Often it is also dispersed and contradictory, and includes duplicates through multiple entries that are not verified and/or matched. Many transformative actions with data are frequently heralded as a big data panacea long before any analytical conclusion can be applied.

This presentation will explore the challenges faced when approaching the question of clinical trial data merging and its interoperability with public clinical trial data for creating valuable insights for study placement.

Meeting Up

ta-Scan’s data team will be present in Washington, D.C. as well to show the precision medicine experts how our clinical business intelligence software ta-Scan can leverage today’s medical big data challenges.

If you want to learn more about our software solutions, you can meet us personally during the exhibition at booth #1 or make an appointment with CSO David Cocker, Director of Business Development, North America Matt Tumasz, or Strategic Data Analyst, Oncology Jonathan Crowther.

Browse categories


Browse tags